CRNX — Crinetics Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $3.47bn
- $2.92bn
- $4.01m
Annual cashflow statement for Crinetics Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -50.4 | -73.8 | -108 | -164 | -215 |
| Depreciation | |||||
| Non-Cash Items | 5.29 | 10.5 | 17 | 29.1 | 39.1 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.13 | 0.376 | 1.1 | 18.6 | 8.04 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -46.4 | -62 | -88.6 | -115 | -166 |
| Capital Expenditures | -0.492 | -0.186 | -0.436 | -1.66 | -4.69 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 42.2 | 0.403 | -56 | -172 | -196 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 41.7 | 0.217 | -56.5 | -174 | -200 |
| Financing Cash Flow Items | — | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.067 | 115 | 253 | 122 | 389 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.65 | 52.8 | 108 | -167 | 22.2 |